Consistently, in the complex cases of the cervical tumor with associated PRL and chemoresistance, the design of a potentially effective treatment protocol could benefit from incorporating drugs that target the different biochemical pathways implicated in promoting the growth of a very aggressive tumor and the associated severe leukocytosis and inflammation. This evidence concerns the gene PRL and neoplasm.